FY2024 Earnings Forecast for GPCR Issued By Lifesci Capital

Structure Therapeutics Inc. (NASDAQ:GPCR) – Stock analysts at Lifesci Capital raised their FY2024 earnings estimates for shares of Structure Therapeutics in a research note issued to investors on Wednesday, November 13th. Lifesci Capital analyst M. Belghiti now expects that the company will earn ($0.75) per share for the year, up from their prior forecast of ($0.87). The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.80) per share. Lifesci Capital also issued estimates for Structure Therapeutics’ Q4 2024 earnings at ($0.19) EPS, Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($0.82) EPS.

Several other equities research analysts have also issued reports on the company. JMP Securities dropped their price target on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research note on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, September 23rd. Finally, Morgan Stanley started coverage on Structure Therapeutics in a research note on Monday, September 23rd. They issued an “overweight” rating and a $118.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $86.80.

Structure Therapeutics Stock Performance

NASDAQ GPCR opened at $34.17 on Monday. The company has a market capitalization of $1.95 billion, a P/E ratio of -46.18 and a beta of -3.23. Structure Therapeutics has a 52-week low of $26.61 and a 52-week high of $66.38. The company has a fifty day moving average of $39.38 and a 200-day moving average of $39.80.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in GPCR. Geode Capital Management LLC boosted its position in Structure Therapeutics by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 45,225 shares of the company’s stock valued at $1,985,000 after buying an additional 312 shares during the period. Squarepoint Ops LLC boosted its holdings in shares of Structure Therapeutics by 4.5% during the second quarter. Squarepoint Ops LLC now owns 14,449 shares of the company’s stock worth $567,000 after purchasing an additional 617 shares during the period. Assetmark Inc. boosted its holdings in shares of Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after purchasing an additional 719 shares during the period. Sandia Investment Management LP bought a new stake in shares of Structure Therapeutics in the second quarter worth about $39,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Structure Therapeutics by 60.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock valued at $158,000 after purchasing an additional 1,420 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.